Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Topics
Piramal | Piramal Enterprises | Stock Market
Photo: Twitter
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Shares of Piramal Pharma closed at Rs 192 on Wednesday during their listing debut.
The company, which got listed separately following its demerger from Piramal Enterprises, was valued at Rs 22,882 crore at last close.
In FY22, the contract development and manufacturing (CDMO) vertical accounted for 59 per cent of its sales, complex hospital generics (CHG), 30 per cent and India consumer products business, 11 per cent.
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock.
“Using sum of the parts (SOTP), we value the CDMO business, CHG, and the ICH business based on 16x, 12x, and 18x FY24E EV/EBITDA respectively. We value Allergan JV (49 per cent stake) based on 18x FY24E PE,” it says.
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, October 19 2022. 18:09 IST
As interest rates climb, troubled companies are facing heightened financial pressures, prompting them to seek assistance... Read more
In the intricate world of financial reporting, auditors serve as guardians of integrity, tasked with uncovering discrepa... Read more
In the competitive landscape of the US banking sector, retaining depositors is paramount for lenders seeking to maintain... Read more
In the realm of banking, the ability to predict and prevent failures is paramount for financial stability and consumer c... Read more
In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more
Author: Ricardo Goulart ... Read more